Moberg Pharma reports progress on MOB-015 launch preparations
First European countries approve rebranding; first deliveries expected year-end. Israel launch planned for Q3 2026.
See the latest news and media coverage for Moberg Pharma. We track all announcements, press releases, and industry mentions in real time, all in one place.
Swedish dermatology pharmaceutical company
mobergpharma.seLast updated
In short: Moberg Pharma significantly expanded its global reach through strategic licensing deals with Karo Healthcare and reported narrowing financial losses.
First European countries approve rebranding; first deliveries expected year-end. Israel launch planned for Q3 2026.
A license agreement enables commercialization of MOB-015 (Terclara) in China through cross-border e-commerce, complementing earlier European and APAC deals.
The meeting approved financial statements, discharged liability, elected new board members including Lars Johansson as Chairman, and resolved on fees and LTI 2026.
Net revenue SEK 4.9 million, EBITDA SEK -1.5 million. Partnership with Karo Healthcare extended to Australia, New Zealand, South Korea, and Taiwan.
The pharmaceutical company Moberg Pharma reports a net loss of SEK 1.3 million for the first quarter of 2026 (loss of SEK 2.8 million). The result...
Moberg Pharma's operating result amounted to -7.5 million kronor for the fourth quarter of 2025 (-308). Sales amounted to 2.1 million kronor (1.0). The net result was -12.8 million...
Moberg Pharma AB ( (SE:MOB)) has provided an update. Moberg Pharma AB has announced a significant expansion into the European market through an exclusive license...
STOCKHOLM, Nov. 5, 2025 /PRNewswire/ -- Moberg Pharma AB (publ) has entered into an exclusive licensing agreement with Karo Healthcare AB regarding the commercialization of...
Track Moberg Pharma and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Discover what's making headlines across other trending companies.